Post-Trial Responsibilities: Ethics and Implementation
Thursday, September 18, 2014 7:30 AM – 5:30 PM
Wasserstein Hall, Milstein East AB, Harvard Law School, 1585 Massachusetts Ave.
The conference is free and open to the public, but due to limited seating, registration is required to attend. Please register here.
The term “post-trial access” is used broadly to connote a wide range of possibilities for providing continued access to study interventions (and potentially other care) once a trial is over, or a subject’s participation has ended. For the purposes of this conference, we will focus discussions on the following:
- Continued access to study intervention(s) and/or other care for people who were enrolled in the clinical trial and were benefiting (whether between the end of the trial and product approval or indefinitely)
- Provision of the study intervention(s) and/or other care to people who were enrolled in the clinical trial but did not get the intervention and would like to try it (whether between the end of the trial and product approval or indefinitely)
- Provision of the study intervention, other care, or other resources to the community in which the trial was conducted
The full background, conference objectives, and agenda are now available on our website.
Cosponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and the Multi-Regional Clinical Trials Center at Harvard University. This event is also supported by the Oswald DeN. Cammann Fund.
